BioBusiness

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Articles

Messenger RNA is inherently unstable and thus requires unique solutions to protect its cohesion.

Finding Solutions to Manage mRNA Instability

Feliza Mirasol is the science editor for 

Deeper biological understanding and technology innovations have improved the fate of ADC development.

ADCs Reap the Benefits of Continual Research and Process Improvements

Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.

A thorough understanding of both regulatory requirements and study challenges can help develop and validate the appropriate methods for a bioanalytical study program.

Aiding Regulatory Submissions Through Robust Bioanalytical Studies

Izaskun Elorza, MD, is the senior medical director for cell and gene therapy at Parexel.

The clinical trial research environment has evolved because of specific solutions designed to overcome uncertainty.

The Evolution of Cellular Therapies in a New Clinical Research Environment

Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.

Synthego Aims to Accelerate Drug Discovery with New Engineered Cell Libraries

The growth in demand of viral-vector-based gene therapies drives continuous efforts to improve viral vector manufacturing.

Driving Manufacturing Improvements Through Viral Vector Advances

Meg Rivers is the former senior editor for 

Avoiding roadblocks through strategic planning early on can help facilitate IND application filings. 

IND Applications Face Challenges Early On in Development Cycle

The recent approvals of bispecific antibodies have opened the gate for the further development of these complex molecules. 

Development of Bispecific Antibodies Pushes Forward

VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.

VeriSIM Life and Mayo Clinic Team Up to Co-develop New Therapies

LG Chem has decided to proceed with IND-enabling studies and has renewed a license with Avacta.

Biologic Drugs in Development